After enduring a two-year diagnostic odyssey, Gregory Maassen received a diagnosis of a postinfectious form of peripheral ...

As Gregory Maassen, Ph.D., prepares to e-bike more than 5,800 miles across the country, he's using the same sense of adventure and skills that he drew ...

(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025, ...

News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Researchers developed a gene therapy for LAMA2-related muscular dystrophy that restored muscle and nerve function in mice. One treatment stabilized disease progression and improved strength, even when ...

Neuropathy – chronic pain, numbness and tingling in the hands and feet – is a challenging fact of life for many patients with ...

Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal ...

Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported ...

Thanks to a new National Institutes of Health grant, a UCF College of Medicine scientist is investigating a new approach to treat neuropathy without relying on pain pills and anti-depressants.